血清溶性ST2受容体の新型心不全バイオマーカーの識別
Ellen O Weinberg1, Masahisa Shimpo, Shelley Hurwitz
1Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Circulation
|February 13, 2003
まとめ
心不全血清に溶けるST2は,神経ホルモンの活性化のための新しいバイオマーカーです. 溶解性ST2レベルの変化は,重度の心不全患者の死亡率または移植を独立して予測します.
科学分野:
- 心臓病学 心臓病学
- バイオマーカーの発見
- ゲノミクスゲノミクスとは
背景:
- インタールイキン-1受容体ファミリーメンバーST2は,心筋細胞の機械的ストレスによって誘発されます.
- 溶解性ST2 (sST2) は,ヒトの血清で分泌され,検出されます.
- この研究では,心不全における神経ホルモン活性化のバイオマーカーとしてsST2を調査した.
研究 の 目的:
- 重度の慢性心不全および神経ホルモンの活性化を有する患者において,溶解性ST2濃度が増加するという仮説を検証する.
- 血清のsST2レベルと既知の神経ホルモンマーカーとの関連性を評価する.
- sST2の変化が,心不全の患者のアウトカムを予測するかどうかを判断する.
主な方法:
- PRAISE-2心不全試験 (NYHAクラスIII-IV) の血清サンプルと臨床データを分析した.
- 溶解性ST2 (sST2) 血清濃度は,ELISAを用いて,ベースラインと2週間で測定されました.
- B型ナトリウレチンペプチド (BNP),プロアトリアルナトリウレチンペプチド (ProANP),ノレピネフリンとの相関が評価されました.
主要な成果:
- ベースラインのsST2レベルは,ベースラインのBNP,ProANP,ノレピネフリンと正に相関していました.
- sST2レベルの変化は,死亡率または移植の有意な単変性予測因子でした.
- 多変量分析では,sST2の変化は,BNPとProANPを考慮した後でも,死亡率/移植の独立した予測因子であり続けました.
結論:
- 血清溶性ST2は,心不全における神経ホルモン活性化のための新しいバイオマーカーです.
- sST2レベルの変化は,重度の慢性心不全 (NYHAクラスIII-IV) の後の死亡率または移植を独立して予測します.
関連する概念動画
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...